Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients

Oral Diseases

Volumn 19, Issue 6, 2013, Pages 577-584

  Turksma, Aw ^a   Bontkes, Hj ^a   van den Heuvel, H ^a   De Gruijl, Td ^a   Von Blomberg, Bme ^a   Braakhuis, Bjm ^a   Leemans, Cr ^a   Bloemena, E ^a,b   Meijer, Cjlm ^a   Hooijberg, E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Head and neck cancer; HPV; Peripheral blood lymphocytes; Prognostic factor; T cell subpopulations

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER LOCALIZATION; CANCER STAGING; FEMALE; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX; LARYNX; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MOUTH CAVITY; OROPHARYNX; PRIORITY JOURNAL; WART VIRUS;

HEAD AND NECK CANCER; HPV; PERIPHERAL BLOOD LYMPHOCYTES; PROGNOSTIC FACTOR; T CELL SUBPOPULATIONS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD27; ANTIGENS, CD3; ANTIGENS, CD45; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LARYNGEAL NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PILOT PROJECTS; T-LYMPHOCYTE SUBSETS;

EID: 84880257205     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12037     Document Type: Article

References (51)

1. Ambs S, Marincola FM, Thurin M (2008). Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy. Cancer Res 68: 4031-4033.
2. Ang KK, Harris J, Wheeler R et al (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35.
3. Bachtiary B, Herbacek I, Zideck T et al (2005). Impact of radiotherapy with and without concurrent cisplatin on lymphocyte subpopulations in cervical cancer patients. Anticancer Res 25: 4673-4678.
4. Badoual C, Hans S, Rodriguez J et al (2006). Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12: 465-472.
5. Braakhuis BJ, Snijders PJ, Keune WJ et al (2004). Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96: 998-1006.
6. Brennan JA, Boyle JO, Koch WM et al (1995). Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 712-717.
7. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS (2010). Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2: 15.
8. Derhovanessian E, Solana R, Larbi A, Pawelec G (2008). Immunity, ageing and cancer. Immun Ageing 5: 11.
9. Di MD, Azevedo RI, Henson SM et al (2011). Reversible senescence in human CD4+ CD45RA+. J Immunol 187: 2093-2100.
10. Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS (2011). Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 13: 393-400.
11. Fakhry C, Westra WH, Li S et al (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269.
12. Galon J, Pages F, Marincola FM et al (2012). The Immune Score as a new possible approach for the classification of cancer. J Transl Med 10: 1.
13. Hamann D, Baars PA, Rep MH et al (1997). Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186: 1407-1418.
14. Heusinkveld M, Goedemans R, Briet RJ et al (2012). Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 131: E74-85.
15. Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren GJ (1994). Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 57: 805-813.
16. Hoffmann TK, Dworacki G, Tsukihiro T et al (2002). Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8: 2553-2562.
17. Hong AM, Dobbins TA, Lee CS et al (2010). Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 103: 1510-1517.
18. Jorritsma A, Schumacher TN, Haanen JB (2009). Immunotherapeutic strategies: the melanoma example. Immunotherapy 1: 679-690.
19. Kacani L, Wurm M, Schennach H, Braun I, Andrle J, Sprinzl GM (2003). Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes. Oral Oncol 39: 672-679.
20. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150.
21. Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG (2006). Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol 67: 863-873.
22. Klussmann JP, Weissenborn SJ, Wieland U et al (2001). Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92: 2875-2884.
23. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL (2004). Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 3755-3762.
24. Lajer CB, von Buchwald C (2010). The role of human papillomavirus in head and neck cancer. APMIS 118: 510-519.
25. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J (2009). Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 27: 1992-1998.
26. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011). The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
27. Linton PJ, Dorshkind K (2004). Age-related changes in lymphocyte development and function. Nat Immunol 5: 133-139.
28. Mackay IR, Goodyear MD, Riglar C et al (1984). Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. Cancer 53: 2619-2627.
29. Marur S, D'Souza G, Westra WH, Forastiere AA (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781-789.
30. Matta A, Ralhan R (2009). Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 1: 6.
31. Melief CJ, van der Burg SH (2008). Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8: 351-360.
32. van Monsjou HS, van Velthuysen ML, van den Brekel MW, Jordanova ES, Melief CJ, Balm AJ (2012). Human papillomavirus status in young patients with head and neck squamous cell carcinoma. Int J Cancer 130: 1806-1812.
33. Moore SR, Johnson NW, Pierce AM, Wilson DF (2000). The epidemiology of mouth cancer: a review of global incidence. Oral Dis 6: 65-74.
34. Pievani A, Borleri G, Pende D et al (2011). Dual-functional capability of CD3+ CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118: 3301-3310.
35. Rietbergen MM, Leemans CR, Bloemena E et al (2012). Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer, doi:10.1002/ijc.27821 [Epub ahead of print].
36. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL (1999). Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 5: 1263-1273.
37. Sanders AE, Slade GD, Patton LL (2012). National prevalence of oral HPV infection and related risk factors in the U.S. adult population. Oral Dis 18: 430-441.
38. Santin AD, Bellone S, Palmieri M et al (2003). Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 89: 271-280.
39. Scholten KB, Turksma AW, Ruizendaal JJ et al (2011). Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med 9: 147.
40. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E (2003). In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 171: 2912-2921.
41. Smeets SJ, Braakhuis BJ, Abbas S et al (2006). Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25: 2558-2564.
42. Sobin L, Gospodarowicz M, Wittekind C. (2009). TNM classification of malignant tumours, 7th edn. Wiley-Blackwell: Hoboken, NJ. ISBN: 1444332414 ISBN-13: 978144433241.
43. Stanley MA (2009). Immune responses to human papilloma viruses. Indian J Med Res 130: 266-276.
44. Steele JC, Mann CH, Rookes S et al (2005). T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 93: 248-259.
45. Vu HL, Sikora AG, Fu S, Kao J (2010). HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 288: 149-155.
46. Wansom D, Light E, Worden F et al (2010). Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 136: 1267-1273.
47. Wansom D, Light E, Thomas D et al (2012). Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 122: 121-127.
48. Woodland DL, Blackman MA (2006). Immunity and age: living in the past? Trends Immunol 27: 303-307.
49. Wu A, Zeng Q, Kang TH et al (2011). Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther 18: 304-312.
50. Yang BB, Jiang H, Chen J, Zhang X, Ye JJ, Cao J (2010). Dendritic cells pulsed with GST-EGFR fusion protein: effect in antitumor immunity against head and neck squamous cell carcinoma. Head Neck 32: 626-635.
51. Zitvogel L, Kepp O, Kroemer G (2011). Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8: 151-160.